We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited small artery disease of mid-adulthood caused by mutations of the NOCTH3 gene on chromosome 19. Ischemic manifestations are the most frequent clinical events in CADASIL: 60-85% of patients have had transient ischemic attacks (TIAs) or complete strokes. Magnetic resonance imaging (MRI) shows on T2-weighted images widespread areas of increased signal in the white matter associated with focal hyperintensities in the basal ganglia, thalamus, and brainstem. Diagnostic testing with immunostaining using anti-NOCTH3 antibodies is an alternative method that seems easier than electronmicroscopy and particularly useful before initiating a complete screening of the gene in difficult cases. As CADASIL is a vascular disorder responsible for cerebral ischemic events, different authors prescribe aspirin for secondary prevention, but its benefit in the disease has not been shown. Treatment of migraine should be restricted to analgesic agents and nonsteroidal anti-inflammatory drugs.